Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
1,455
Views
3
CrossRef citations to date
0
Altmetric
Economic Evaluations

Does meta-analysis of economic evaluations have the potential to play a role in healthcare decision-making in the United States?

Sajesh K. Veettila Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
,
M. Sakil Syeeda Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA
,
Rini Noviyanb Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Udayana University, Jimbaran, Bali, Indonesia
,
Ammarin Thakkinstianc Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi, Hospital, Mahidol University, Bangkok, Thailand;d Health Technology Assessment Graduate Program, Mahidol University, Bangkok, Thailand
&
Nathorn Chaiyakunapruka Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA;e IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USACorrespondence[email protected]
Pages 750-754 | Received 13 Apr 2022, Accepted 25 May 2022, Published online: 06 Jun 2022

References

  • Kim DD, Basu A. How does cost-effectiveness analysis inform health care decisions? AMA J Ethics. 2021;23(8):750–647.
  • Dooling KL. Recommendations of the advisory committee on immunization practices for use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018;67.
  • Pearson SD, Emond SK. How independent assessment of drug value can help states. 2022; [cited 2022 May 23]. Available from: https://icer.org/news-insights/commentaries/how-independent-assessment-of-drug-value-can-help-states/.
  • Lising A, Drummond M, Barry M, et al. Payers’ use of independent reports in decision making – will there be an ICER effect?. Value Outcomes Spotlight. 2017. https://www.ispor.org/publications/journals/value-outcomes-spotlight/abstract/march-april-2017/payers-use-of-independent-reports-in-decision-making-will-there-be-an-icer-effect.
  • Garrison LP, Neumann PJ, Willke RJ, et al. A health economics approach to US value assessment frameworks-summary and recommendations of the ISPOR special task force report. Value Health. 2018;21(2):161–165.
  • Fazio L, Rosner A, Drummond M. How do U.S. payers use economic models submitted by life sciences organizations? Value Outcomes Spotlight. 2016;2(2):18–21.
  • Richardson JS, Messonnier ML, Prosser LA. Preferences for health economics presentations among vaccine policymakers and researchers. Vaccine. 2018;36(43):6416–6423.
  • Biskupiak J, Oderda G, Brixner D, et al. Payer perceptions on the use of economic models in oncology decision making. J Manag Care Spec Pharm. 2021;27(11):1560–1567.
  • van Mastrigt GAPG, Hiligsmann M, Arts JJC, et al. How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3). Expert Rev Pharmacoecon Outcomes Res. 2016;16(6):689–704.
  • Higgins JPT, Green S (Editors). Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [Updated March 2011]. The Cochrane Collaboration, 2011. Available from www.Handbook.Cochrane.Org.
  • Crespo C, Monleon A, Díaz W, et al. Comparative efficiency research (COMER): meta-analysis of cost-effectiveness studies. BMC Med Res Methodol. 2014;14(1):139.
  • Bagepally BS, Chaikledkaew U, Chaiyakunapruk N, et al. Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Serv Res. 2022;22(1):202.
  • World Health Organization. Meeting of the immunization and vaccine-related Implementation Research Advisory Committee (IVIR-AC). 2021;96(17):133–143.
  • Prosser LA, Harpaz R, Rose AM, et al. A cost-effectiveness analysis of vaccination for prevention of Herpes Zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170(6):380–388.
  • Carpenter CF, Aljassem A, Stassinopoulos J, et al. A cost-effectiveness analysis of an adjuvanted subunit vaccine for the prevention of Herpes Zoster and post-herpetic Neuralgia. Open Forum Infect Dis. 2019;6(7):ofz219.
  • Curran D, Patterson BJ, Van Oorschot D, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Hum Vaccin Immunother. 2019;15(4):765–771.
  • Le P, Rothberg MB. Cost effectiveness of a shingles vaccine Booster for currently vaccinated adults in the U.S. Am J Prev Med. 2017;53(6):829–836.
  • Shields GE, Elvidge J. Challenges in synthesising cost-effectiveness estimates. Syst Rev. 2020;9(1):289.
  • Noviyani R, Youngkong S, Nathisuwan S, et al. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and Meta-analysis. Bmj EBM. 2021;2021:bmjebm-2020-111634.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.